2025 annual financial data
Spyre Therapeutics 2025 Operating margin
Direct answer
Operating margin was Not calculable.
Operating income was -209,562,000 USD and net income was -155,203,000 USD.
Operating cash flow was -169,252,000 USD.
Get free Spyre Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -209,562,000 USD
- Net income
- -155,203,000 USD
- Operating cash flow
- -169,252,000 USD